Several other equities research analysts have also commented on the stock. Cantor Fitzgerald reissued a hold rating and issued a $19.00 price target (up previously from $15.00) on shares of Omeros Corporation in a report on Thursday, August 24th. Zacks Investment Research cut shares of Omeros Corporation from a buy rating to a hold rating in a research report on Wednesday, October 25th. Maxim Group set a $24.00 price target on shares of Omeros Corporation and gave the company a buy rating in a research report on Friday, October 20th. Finally, Wedbush reissued an outperform rating and set a $47.00 price target on shares of Omeros Corporation in a research report on Friday, August 18th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $34.14.
Shares of Omeros Corporation (OMER) traded up $0.16 during trading on Thursday, hitting $18.97. 1,088,900 shares of the stock were exchanged, compared to its average volume of 803,570. The company has a current ratio of 4.77, a quick ratio of 4.74 and a debt-to-equity ratio of 8.99. Omeros Corporation has a 52-week low of $8.71 and a 52-week high of $27.09.
Omeros Corporation (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.18. The business had revenue of $21.66 million for the quarter, compared to analyst estimates of $17.82 million. During the same quarter in the previous year, the firm posted ($0.34) earnings per share. The business’s revenue was up 91.9% on a year-over-year basis. equities research analysts expect that Omeros Corporation will post -1.32 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Cowen and Company Downgrades Omeros Corporation (NASDAQ:OMER) to Market Perform” was originally posted by BBNS and is owned by of BBNS. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://baseballnewssource.com/markets/omeros-corporation-omer-rating-lowered-to-market-perform-at-cowen-and-company/1752753.html.
A number of institutional investors have recently added to or reduced their stakes in OMER. Legal & General Group Plc increased its position in Omeros Corporation by 7.8% during the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 751 shares in the last quarter. Rhumbline Advisers grew its holdings in Omeros Corporation by 1.8% in the 2nd quarter. Rhumbline Advisers now owns 46,632 shares of the biopharmaceutical company’s stock valued at $928,000 after buying an additional 832 shares during the period. Wells Fargo & Company MN grew its holdings in Omeros Corporation by 5.5% in the 1st quarter. Wells Fargo & Company MN now owns 37,717 shares of the biopharmaceutical company’s stock valued at $571,000 after buying an additional 1,960 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in Omeros Corporation by 1.3% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 197,665 shares of the biopharmaceutical company’s stock valued at $3,935,000 after buying an additional 2,548 shares during the period. Finally, American International Group Inc. grew its holdings in Omeros Corporation by 15.2% in the 1st quarter. American International Group Inc. now owns 24,521 shares of the biopharmaceutical company’s stock valued at $371,000 after buying an additional 3,232 shares during the period. 45.37% of the stock is owned by institutional investors.
About Omeros Corporation
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with our FREE daily email newsletter.